1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992


Delayed Swiss Exchange  -  05/20 11:30:40 am EDT
55.20 CHF   +0.36%
04/22BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022
04/22BB Biotech Swings To Q1 Loss As Total Returns Plummet
04/22BB Biotech AG publishes its interim report
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BB Biotech : publishes interim report

04/25/2021 | 09:12am EDT

Important information

Please read this page for your own protection before continuing as it contains legal provisions regarding the distribution of this information.

The information contained on the following pages is exclusively directed at investors who are resident or have their registered office in Switzerland.
The information and contents of this website do not constitute an order or an offer to purchase or to sell financial products or financial services in countries in which such activities are contrary to legal provisions.

By clicking on the 'Accept' button, you confirm that you are resident or have your registered office in Switzerland, and that you have read and understood the legal notices below, and agree to the provisions of said legal notices. Please read them carefully.
If you do not agree to the provisions of the legal notices, you may not refer to or use the website.

Conditions of use and exclusion of liability

By visiting and accessing this website ('website') you acknowledge, without restrictions of any kind, the legally binding nature of the conditions of use and the exclusion of liability as set out here ('conditions of use').

Please read through these conditions carefully before you visit our website and access its content. If you do not agree to these conditions of use you should refrain from accessing any further pages of this website. Please also read the additional legal information that applies in respect of your country.

These conditions of use and all information and material on the website may be updated at any time without prior notice. Since all updated versions of these conditions of use will also be binding for you, we recommend that you check these on a regular basis.

Access is subject to local restrictions

Neither the website nor the information and functions contained on the website are directed to or intended for persons who live in the sphere of validity of laws according to which the dissemination of this information or these functions is unlawful, or for whom dissemination thereof is prohibited without prior licensing or approval from the competent supervisory authority (and the licenses and approvals in question have not been obtained).

Under certain circumstances, shares in BB Biotech AG cannot be acquired by persons who are resident in certain countries, or by certain categories of investors. Important information in this regard can be found in the applicable provisions such as sales restrictions or important special notices.

No offer is made

The material offered on the website, and the information contained and opinions expressed therein, do not relate to special investment goals or to the financial situation or particular requirements of specific users.

It is not the intention of BB Biotech AG to offer investment, legal or tax advice via its website, neither does BB Biotech AG offer any guarantee that the securities discussed on this website are suitable for any particular investor.

All information presented, reports published and opinions expressed on this website are intended purely for information purposes, and do not constitute an offer for the conclusion of a contract or other legal transaction. In particular, the content of the website is not to be understood as an invitation or recommendation to buy or sell securities of BB Biotech AG, or as an advertisement for securities of BB Biotech AG. Neither does it constitute an offer to participate in any other transaction, including (but not restricted to) trading in derivatives.

The mere use of the website does not give rise to any contractual relationship of any kind between the user and BB Biotech AG.

Information concerning price developments

BB Biotech AG expressly draws your attention to the fact that its share price is subject to fluctuation, and that the future development of the share price cannot be derived either from the previous price history or from the information and content shown on this website. Results achieved in the past provide no guarantee in regard to the future development of the share price. All figures shown are purely a representation of past price changes and therefore do not allow conclusions of any kind in regard to the performance of BB Biotech AG in the future.

The value of investments can also be negatively influenced by changes in currency exchange rates and changes in the political and economic situation, and also by illiquidity of the markets. The possibility that investments and earnings may lose in value cannot be ruled out. It is entirely possible for investors to lose the entire amount invested.

BB Biotech AG provides no guarantee of any kind that the capital invested will increase in value or maintain its value. In light of these given risks, we strongly advise you to seek professional advice before making any investment decision.

No warranty or guarantee provided

The information on this website relating to investments, prices, securities prices and net asset values is subject to frequent change and is regularly updated by BB Biotech AG or updated on the basis of other sources. However, BB Biotech AG does not provide any express or implicit guarantee in regard to the accuracy, completeness or reliability of this information. The information stated on the website does not represent any complete statement concerning the securities, markets and developments to which it relates. You should therefore not rely on this information, neither should you use it for any formal analysis or estimation or as the basis for an investment decision.

The material contained on the website does not relieve the user from having to make his own decisions. Any views expressed can change without prior notice or can on the basis of different assumptions and criteria deviate from or contradict views that are represented by companies instructed by BB Biotech AG. BB Biotech AG is not obliged to update the information contained on this website or to keep the information up to date.

Exclusion of liability

BB Biotech AG, its affiliated company Bellevue Asset Management AG and their information providers expressly accept no liability for consequences of actions or omissions based on reliance on all or part of the information on this website.

In addition BB Biotech AG, Bellevue Asset Management AG and their information providers also accept no liability for loss or damage that may arise as a result of the use of or reliance on the information published on the website, or for possible loss of profit or other direct or indirect loss or damage. This exclusion of liability applies also in respect of liability based on negligence, and applies even if BB Biotech AG was informed of the possibility of such consequences.

You hereby declare that your use of this website is therefore at your own risk, and you acknowledge that all information provided here is provided on an 'as is' basis, and that neither BB Biotech AG, Bellevue Asset Management AG nor their information providers give any assurances or guarantees of any kind, either express or implied, with regard to the data provided, including (but not limited to) its merchantability, non-violation of third-party rights, title, or suitability for any particular purpose or any particular use.

BB Biotech AG, Bellevue Asset Management AG and their information providers provide no guarantee that the content of this website is compatible with your technical equipment or that it is free from defects or viruses, worms or Trojan horses, and accept no liability for any damage suffered by you as a result of such destructive characteristics.

You hereby declare that BB Biotech AG, Bellevue Asset Management AG and their information providers, and also their suppliers and executive agents, shall not be liable for:

(a) any injury or damage, irrespective of whether the injury or damage in question was caused as a result of negligence on the part of BB Biotech AG, Bellevue Asset Management AG, or their information providers, or by their employees, contracting partners, executive agents or suppliers, or in any other way in connection with this website;

(b) any errors, inaccuracies, omissions or delays, or failure of any other kind caused by your technical equipment or by your use of this website on your technical equipment.

BB Biotech AG, Bellevue Asset Management AG and their information providers give no assurances regarding, and are not responsible for, the reliability or continuing availability of the telephone lines and the technical equipment you use to access this website. You are aware that BB Biotech AG and/or other parties participating in this website can decide at any time without prior warning to prevent or prohibit access to their content or to make a charge for the use of their content.

Links to websites of third parties

This website may contain links to external websites of third parties (external links) the content of which is outside the sphere of influence of BB Biotech AG. Visiting and using such websites that are accessible via such links are subject to the conditions of the data protection policy of these websites and the liability of the respective operators. BB Biotech AG accepts no responsibility and offers no guarantee of any kind for the content or websites of third parties, and gives no assurances of any kind in this regard. BB Biotech AG accepts no responsibility for the data protection policy and customer information of Internet websites of third parties, and shall not be liable for the content or web pages of third parties which are linked to the BB Biotech AG website or which display the BB Biotech AG website in frames.

Copyright and right of communication

The entire content of this website is subject to copyright and all rights thereto are reserved.

All trademarks, service marks, trade names, logos, icons (symbols) and domain names are the property of BB Biotech AG, Bellevue Asset Management AG or their information providers and/or the subsidiaries thereof. Nothing which is contained in this website provides you, without the prior written permission of BB Biotech AG, Bellevue Asset Management AG or their information providers, any license or right to use any property of any kind belonging to BB Biotech AG, Bellevue Asset Management AG or their information providers and/or the subsidiaries thereof. Any non-permitted use of the content of this website may constitute an infringement of copyright, trademark rights, rights of personality and rules of communication.

The information offered on this website is available for personal use only. Any commercial or public use of this website or of any of its parts is strictly prohibited. Without the written agreement of BB Biotech AG, no material from this website may be copied, reproduced, republished, transmitted or distributed in any way. You may download the material displayed on this website for non-commercial, personal use, provided you observe all copyright and ownership notices as contained in this material.


BB Biotech AG and Bellevue Asset Management AG / their subsidiaries and/or directors, management members and salaried employees are permitted, at the present time, in the past and in the future, to enter into, hold or sell investments in the investment possibilities referred to on this website, within the framework of the applicable laws in this regard.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Place of jurisdiction

By visiting this website you agree to be subject to the exclusive jurisdiction of the courts of the Canton of Schaffhausen (Switzerland), where the registered office of BB Biotech AG is situated.


BB Biotech AG published this content on 23 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2021 13:11:09 UTC.

© Publicnow 2021
All news about BB BIOTECH AG
04/22BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022
04/22BB Biotech Swings To Q1 Loss As Total Returns Plummet
04/22BB Biotech AG publishes its interim report
04/22BB BIOTECH AG : Increased investment level balanced by established core holdings
04/12GLOBAL MARKETS LIVE : Honda, Shopify, Meta, ASOS, Gilead Sciences...
04/12BB Biotech Launches New Share Repurchase Program
04/12BB Biotech AG concludes its share buyback program and launches a new buyback program
04/12Tranche Update on BB Biotech AG’s Equity Buyback Plan announced on April 11, 2019.
04/12BB Biotech AG authorizes a Buyback Plan.
04/12BB Biotech AG announces an Equity Buyback.
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Sales 2022 796 M 815 M 815 M
Net income 2022 497 M 509 M 509 M
Net Debt 2022 278 M 285 M 285 M
P/E ratio 2022 4,16x
Yield 2022 7,32%
Capitalization 3 043 M 3 119 M 3 119 M
EV / Sales 2022 4,18x
EV / Sales 2023 4,98x
Nbr of Employees 10
Free-Float 98,1%
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 4
Last Close Price 55,20 CHF
Average target price 75,13 CHF
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG-28.45%3 119
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704